Search

In first line, iadademstat with azacitidine and venetoclax continues to show favorable safety and 100% ORR, with a composite complete remission rate (CRc) of 93% (with 79% CR), and an estimated 12

These results come from a preclinical study conducted by the Cell Engineering team at Integra Therapeutics using the FiCAT gene-writing platform.

Meet AllBiotech, our new member. We spoke with Pablo Goñi, CEO.

The company presented its new Branded Ingredient at Vitafoods Europe, the nutraceutical industry trade show, which took place this week in Barcelona

The Dutch company is bolstering Málaga’s advanced technology ecosystem with a total investment of €32 million.

Innovation in healthcare does not arise solely from good ideas, but from an institutional architecture capable of attracting talent, coordinating capabilities and accelerating translation.

The agreement combines the preclinical models developed by the Institute of Biomedical Research of Barcelona (IIBB-CSIC) with the computational design platform of the company Chemotargets, based at

Meet PLOID AI, our new member. We spoke with Adolfo Gastalver Rubio and Federico Jurado Ruiz, CO-Founders.

Updated data from iadademstat’s clinical trials in acute myeloid leukemia to be presented at EHA-2026 in June.

MedTech Barcelona took part in the Spain–United States Business Meeting in Boston, held on April 13 and 14.

The Bilbao Exhibition Centre will host the next edition of BIOSPAIN from September 29 to October 1.